Trial Profile
Analysis of complement activity and eculizumab dosage in patients with Paroxysmal nocturnal hemoglobinuria (PNH)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Dec 2015
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Pharmacokinetics
- 29 Dec 2015 New trial record